Use: Labeled indications
- Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Full indications and usage US FDA label
1 INDICATIONS & USAGE Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate tablets are muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. (1)
Contraindications
4 CONTRAINDICATIONS Solifenacin succinate tablets are contraindicated in patients: With urinary retention [see Warnings and Precautions (5.2)], With gastric retention [see Warnings and Precautions (5.3)], With uncontrolled narrow-angle glaucoma [see Warnings and Precautions (5.5)], and Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. Reported adverse reactions have included anaphylaxis and angioedema [see Adverse Reactions (6.2)].
- Urinary retention. (4, 5.2)
- Gastric retention. (4, 5.3)
- Uncontrolled narrow-angle glaucoma. (4, 5.5)
- Hypersensitivity to this product or any of its components. (4, 5.1, 6.2)
Dosing: Adult
- • 5 mg tablet taken orally once daily, and if well tolerated may be increased to 10 mg once daily. (2.1)
- • Do not exceed the 5 mg dose of solifenacin succinate tablets in patients with: o Severe renal impairment creatinine clearance < 30 mL/min/1.73 m². (2.2, 8.6)
- o Moderate hepatic impairment (Child-Pugh B). Solifenacin succinate tablets are not recommended in patients with severe hepatic impairment (Child-Pugh C). (2.3, 8.7)
- o Concomitant use of strong CYP3A4 inhibitors. (2.4, 7.1)
2.1 Dosing Information
2.1 Dosing Information The recommended oral dose of solifenacin succinate tablets are 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily. Solifenacin succinate tablets should be taken with water and swallowed whole. Solifenacin succinate tablets can be administered with or without food.
2.2 Dosing Recommendations in Patients with Renal Impairment
2.2 Dosing Recommendations in Patients with Renal Impairment Do not exceed 5 mg once daily in patients with severe renal impairment (CLcr < 30 mL/min/1.73 m²) [see Use in Specific Populations (8.6)].
2.3 Dosing Recommendations in Patients with Hepatic Impairment
2.3 Dosing Recommendations in Patients with Hepatic Impairment Do not exceed 5 mg once daily in patients with moderate hepatic impairment (Child-Pugh B). Do not use solifenacin succinate tablets in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7)].
2.4 Dosing Recommendations in Patients Taking CYP3A4 Inhibitors
2.4 Dosing Recommendations in Patients Taking CYP3A4 Inhibitors Do not exceed 5 mg once daily when solifenacin succinate tablets are administered with strong CYP3A4 inhibitors such as ketoconazole [see Drug Interactions (7.1)].
Dosing: Altered kidney function
2.2 Dosing Recommendations in Patients with Renal Impairment Do not exceed 5 mg once daily in patients with severe renal impairment (CLcr < 30 mL/min/1.73 m²) [see Use in Specific Populations (8.6)].
8.6 Renal Impairment Solifenacin plasma concentrations are greater in patients with severe renal impairment compared to subjects with normal renal function [see Clinical Pharmacology (12.3)]. Because increased solifenacin plasma concentrations increase the risk of antimuscarinic adverse reactions, the maximum recommended dose of solifenacin succinate tablets in patients with severe renal impairment (CLcr < 30 mL/min/1.73 m²) is 5 mg once daily [see Dosage and Administration (2.2)].
The recommended dose in patients with mild or moderate renal impairment is the same as in patients with normal renal function.
Patients with Renal Impairment In studies with solifenacin succinate 10 mg, there was a 2.1-fold increase in AUC and a 1.6-fold increase in t1/2 of solifenacin in patients with severe renal impairment compared to subjects with normal renal function [see Use in Specific Populations (8.6)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment Solifenacin plasma concentrations are greater in patients with moderate hepatic impairment compared to subjects with normal hepatic function [see Clinical Pharmacology (12.3)]. Because increased solifenacin plasma concentrations increase the risk of antimuscarinic adverse reactions, the maximum recommended dose of solifenacin succinate tablets in patients with moderate hepatic impairment (Child-Pugh B) is 5 mg once daily [see Dosage and Administration (2.3)] and solifenacin succinate tablets is not recommended for use in patients with severe hepatic impairment (Child-Pugh C).
2.3 Dosing Recommendations in Patients with Hepatic Impairment Do not exceed 5 mg once daily in patients with moderate hepatic impairment (Child-Pugh B). Do not use solifenacin succinate tablets in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of solifenacin succinate tablets have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In placebo-controlled clinical studies, similar safety and effectiveness were observed between geriatric patients (623 patients ≥ 65 years and 189 patients ≥ 75 years) and younger adult patients (1188 patients < 65 years) treated with solifenacin succinate tablets. [see Clinical Pharmacology (12.3)].
Dosage forms
Philippines
- Film-coated tablet: 5 mg, 10 mg
- Tablet: 5 mg, 10 mg
Registered products in the Philippines
33 products registered with the Food and Drug Administration (FDA) Philippines list Solifenacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products33
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Abo 10Solifenacin succinate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare, Inc. | DR-XY48079 | Jun 1, 2027 | |
Abo 5Solifenacin Succinate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Unison Laboratories Co., Ltd.Thailand | Justright Healthcare Inc. | DR-XY48280 | Aug 15, 2027 | |
Blacidec 10Solifenacin Succinate | 10 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | MSN Laboratories Private Limited (Formulations Division) Unit II,India | Macropharma Corporation | DRP-11146 | Feb 11, 2027 | |
Blacidec 5Solifenacin Succinate | 5mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | MSN Laboratories Private Limited (Formulations Division) Unit II,India | MSN Labs Philippines Inc. | DRP-11147 | Feb 11, 2027 | |
DalisoonSolifenacin (as succinate) | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Standard Chem. & Pharm. Co., Ltd.Taiwan | Standard Chem & Pharm. Philippines. Inc. | DRP-15261 | May 31, 2029 | |
Goab 10Solifenacin succinate | 10 mg Film-Coated TabletClear Plain PVC Peel Push Through Blister Pack x 10 (Box of 30's) | Rx | Annora Pharma Private LimitedIndia | Camber Pharmaceuticals, Inc.Trader: Hetero Labs Limited | DRP-14637 | Nov 10, 2028 | |
Goab 5Solifenacin succinate | 5 mg Film-Coated TabletClear Plain PVC Peel Push Through Blister Pack x 10 (Box of 30's) | Rx | Annora Pharma Private LimitedIndia | Camber Pharmaceuticals, Inc.Trader: Hetero Labs Limited | DRP-14636 | Nov 10, 2028 | |
Slonacin-10Solifenacin succinate | 10 mg Film Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 10's and 30's) | Rx | MSN Laboratories Private Limited (Formulations Division, Unit-II)India | Biocare Lifesciences, Inc. | DRP-16991 | Sep 4, 2030 | |
Slonacin-5Solifenacin succinate | 5 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | MSN Laboratories Private Limited (Formulations Division, Unit-II)India | Biocare Lifesciences, Inc. | DRP-16990 | Sep 4, 2030 | |
Solfesire 10Solifenacin Succinate | 10mg Film-Coated TabletClear PVC/PVDC Blister Pack x 10’s (Box of 30’s, 60’s & 100’s) | Rx | Humanis Sağlik Anonim ŞirketiTurkey | Despina Pharma Inc. | DRP-18672 | Aug 26, 2030 | |
Solfesire 5Solifenacin Succinate | 5mg Film-Coated TabletClear PVC/PVDC Blister Pack x 10’s (Box of 30’s, 60’s & 100’s) | Rx | Humanis Sağlik Anonim ŞirketiTurkey | Despina Pharma Inc. | DRP-18673 | Aug 26, 2031 | |
Solfinova 10Solifenacin Succinate | 10 mg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | Rx | Unison Pharmaceuticals Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-15657 | Aug 15, 2029 | |
Solfinova 5Solifenacin Succinate | 5 mg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | Rx | Unison Pharmaceuticals Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-15656 | Aug 15, 2029 | |
Solicare 10Solifenacin succinate | 10 mg Film-Coated TabletPVC/PE/PVDC/Aluminum Blister Pack x 10's (Box of 30's, 60's and 100's) | Rx | Genepharm S.A.Greece | Despina Pharma Inc. | DRP-17261 | Nov 3, 2030 | |
Solicare 5Solifenacin succinate | 5 mg Film-Coated TabletPVC/PE/PVDC/Aluminum Blister Pack x 10's (Box of 30's, 60's and 100's) | Rx | Genepharm S.A.Greece | Despina Pharma Inc. | DRP-17260 | Nov 3, 2030 | |
SolifSolifenacin Succinate | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | Genace Pharma DistributorImporter: AMB HK Enterprises Inc. | DRP-14623-01 | Nov 10, 2028 | |
SolifenSolifenacin Succinate | 10mg Film-Coated TabletAlu - Alu Blister Pack x 10's (Box of 30's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY48357 | Sep 15, 2027 | |
SolifenSolifenacin Succinate | 5mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY48356 | Sep 15, 2027 | |
SolifinaSolifenacin Succinate | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-14623 | Nov 10, 2028 | |
SolifinaSolifenacin Succinate | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises IncImporter: AMB HK Enterprises Inc. | DRP-14624 | Nov 10, 2028 | |
SoligenSolifenacin Succinate | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | Genace Pharma DistributorImporter: AMB HK Enterprises Inc. | DRP-14623-02 | Nov 10, 2028 | |
SoligenSolifenacin Succinate | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | Genace Pharma DistributorImporter: AMB HK Enterprises Inc. | DRP-14624-01 | Nov 10, 2028 | |
SolinSolifenacin Succinate | 5 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 14's (Box of 28's) | Rx | Synmosa Biopharma Corporation (Synmosa Plant)Taiwan | Synmosa Biopharma Philippines Inc. | DRP-17445 | Jun 17, 2031 | |
Solitor 10Solifenacin Succinate | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DRP-10973 | Dec 27, 2026 | |
Solitor 5Solifenacin succinate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48001 | May 5, 2027 | |
UrgisoSolifenacin Succinate | 10 mg Film-Coated TabletAlu/PVC Blister Pack by 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY47876 | Apr 1, 2027 | |
UrgisoSolifenacin Succinate | 5 mg Film-Coated TabletAlu/PVC Blister Pack by 10's (Box of 30's) FDA | Rx | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY47877 | Apr 1, 2027 | |
VesicareSolifenacin succinate | 10 mg Film-coated TabletPVC/Alu Blister Pack x 10's Box of 30's | Rx | Astellas Pharma Europe B.V.Netherlands | Zuellig Pharma CorporationImporter: Astellas Pharma Philippines, Inc. | DR-XY31760 | Oct 10, 2029 | |
VesicareSolifenacin succinate | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack of 10's Box of 30's | Rx | Delpharm Meppel B.V.Netherlands | Zuellig Pharma CorporationImporter: Astellas Pharma Philippines, Inc. | DR-XY31747 | Nov 9, 2030 | |
VesifixSolifenacin Succinate | 10 mg Film-Coated TabletAlu/PVC/Aclar/PVDC/PVC Transparent Clear Blister Pack x 10's (Box of 30's) | Rx | Nobel llac Sanayi Ve Ticaret A.S.Turkey | Genace Pharma DistributorImporter: Ambicare Pharmaceuticals, Inc. | DRP-8922 | Jun 28, 2027 | |
VesifixSolifenacin succinate | 5 mg Film-Coated TabletAlu/PVC/Aclar/PVDC/PVC Transparent clear blister pack x 10's (Box of 30's) | Rx | Nobel Ilac Sanayii ve Ticaret A.S.Turkey | Genace Pharma DistributorImporter: Ambicare Pharmaceuticals Inc. | DRP-8921 | Jun 24, 2030 | |
Vesizen 10Solifenacin succinate | 10 mg Film-Coated TabletPVC/PVDC clear film blister pack x 10's (box of 3 blister packs x 10 tablets) | Rx | Sun Pharma Laboratories Ltd.India | Sun Pharma Philippines, Inc. | DRP-14166 | Jul 7, 2028 | |
Vesizen 5Solifenacin succinate | 5 mg Film-Coated TabletPVC/PVDC clear film blister pack x 10's (box of 3 blister packs x 10 tablets) | Rx | Sun Pharma Laboratories Ltd.India | Sun Pharma Philippines, Inc. | DRP-14165 | Jul 7, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS & STRENGTHS Tablets: The 5 mg tablets are light yellow colored, round, biconvex, film coated tablets debossed with "L22" on one side and plain on other side. The 10 mg tablets are pinkish white colored, round, biconvex, film coated tablets debossed with "L 27" on one side and plain on other side. Tablets: 5 mg and 10 mg. (3)
Warnings/Precautions
- • Angioedema and Anaphylactic Reactions: Promptly discontinue solifenacin succinate tablets and provide appropriate therapy. (5.1)
- • Urinary Retention: solifenacin succinate tablets is not recommended for use in patients with clinically significant bladder outlet obstruction. (5.2)
- • Gastrointestinal Disorders: solifenacin succinate tablets are not recommended for use in patients with decreased gastrointestinal motility. (5.3)
- • Central Nervous System Effects: Somnolence has been reported with solifenacin succinate tablets. Advise patients not to drive or operate heavy machinery until they know how solifenacin succinate tablets affect them. (5.4)
- • Controlled Narrow-Angle Glaucoma: Use solifenacin succinate tablets with caution in patients being treated for narrow-angle glaucoma. (5.5)
- • QT Prolongation in Patients at High Risk of QT Prolongation: solifenacin succinate tablets is not recommended for use in patients at high risk of QT prolongation, including patients with a known history of QT prolongation and patients taking medications known to prolong the QT interval. (5.6)
5.1 Angioedema and Anaphylactic Reactions
5.1 Angioedema and Anaphylactic Reactions Angioedema of the face, lips, tongue, and/or larynx have been reported with solifenacin succinate. In some cases, angioedema occurred after the first dose, however, cases have been reported to occur hours after the first dose or after multiple doses. Anaphylactic reactions have also been reported in patients treated with solifenacin succinate.
Angioedema associated with upper airway swelling and anaphylactic reactions may be life-threatening. Solifenacin succinate tablets are contraindicated in patients with a known or suspected hypersensitivity to solifenacin succinate [see Contraindications (4)]. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue solifenacin succinate tablets and provide appropriate therapy and/or measures necessary to ensure a patent airway.
5.2 Urinary Retention
5.2 Urinary Retention The use of solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. The use of solifenacin succinate tablets are not recommended in patients with clinically significant bladder outlet obstruction and is contraindicated in patients with urinary retention [see Contraindications (4)].
5.3 Gastrointestinal Disorders
5.3 Gastrointestinal Disorders The use of solifenacin succinate tablets, like other antimuscarinic drugs, in patients with conditions associated with decreased gastrointestinal motility may result in further decreased gastrointestinal motility. solifenacin succinate tablets are contraindicated in patients with gastric retention [see Contraindications (4)]. The use of solifenacin succinate tablets are not recommended in patients with conditions associated with decreased gastrointestinal motility.
5.4 Central Nervous System Effects
5.4 Central Nervous System Effects Solifenacin succinate tablets are associated with antimuscarinic central nervous system (CNS) adverse reactions [see Adverse Reactions (6.2)]. A variety of CNS antimuscarinic adverse reactions have been reported, including headache, confusion, hallucinations, and somnolence. Monitor patients for signs of antimuscarinic CNS adverse reactions, particularly after beginning treatment or increasing the dose.
Advise patients not to drive or operate heavy machinery until they know how solifenacin succinate tablets affect them. If a patient experiences antimuscarinic CNS adverse reactions, consider dose reduction or drug discontinuation.
5.5 Controlled Narrow-Angle Glaucoma
5.5 Controlled Narrow-Angle Glaucoma Solifenacin succinate tablets should be used with caution in patients being treated for narrow-angle glaucoma [see Contraindications (4)].
5.6 QT Prolongation in Patients at High Risk of QT
5.6 QT Prolongation in Patients at High Risk of QT Prolongation In a study of the effect of solifenacin succinate on the QT interval conducted in 76 healthy women [see Clinical Pharmacology (12.2)], solifenacin succinate 30 mg (three times the largest maximum recommended dose in adult patients) was associated with a mean increase in the Fridericia-corrected QT interval of 8 msec (90% CI, 4, 13). The QT prolonging effect appeared less with solifenacin succinate 10 mg than with solifenacin succinate 30 mg, and the effect of solifenacin succinate 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
The use of solifenacin succinate tablets is not recommended in patients at high risk of QT prolongation, including patients with a known history of QT prolongation and patients who are taking medications known to prolong the QT interval.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS CYP3A4 Inhibitors: Do not exceed the 5 mg dose of solifenacin succinate tablets with concomitant use of strong CYP3A4 inhibitors. (7.1) 7.1 Strong CYP3A4 Inhibitors Solifenacin is a substrate of CYP3A4. Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [see Clinical Pharmacology (12.3)]. The dosage of solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration (2.4)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist.
Drug Interaction Studies Strong CYP3A4 Inhibitors In a crossover study, following blockade of CYP3A4 by coadministration of the strong CYP3A4 inhibitor, ketoconazole 400 mg once daily for 21 days, the mean C max and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively [see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7.1 )].
CYP3A4 Inducers Because solifenacin is a substrate of CYP3A4, inducers of CYP3A4 may decrease the concentration of solifenacin.
Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies demonstrated that, at therapeutic concentrations, solifenacin does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver microsomes.
7 DRUG INTERACTIONS CYP3A4 Inhibitors: Do not exceed the 5 mg dose of solifenacin succinate tablets with concomitant use of strong CYP3A4 inhibitors.
( 7.1 ) 7.1 Strong CYP3A4 Inhibitors Solifenacin is a substrate of CYP3A4.
Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [see Clinical Pharmacology ( 12.3 )].
The dosage of solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )].
Adverse reactions
- The most common adverse reactions (> 4% in solifenacin succinate tablets -treated patients and > placebo-treated patients) were dry mouth and constipation at both 5 mg and 10 mg doses; and urinary tract infection and blurred vision at the 10 mg dose. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Solifenacin succinate tablets have been evaluated for safety in 1811 adult patients in four randomized, placebo-controlled trials (Studies 1-4) [see Clinical Studies (14)].
Expected adverse reactions of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The incidence of dry mouth and constipation in patients treated with solifenacin succinate tablets was higher in the 10 mg dose group compared to the 5 mg dose group.
In the four 12-week double-blind clinical trials, severe fecal impaction, colonic obstruction, and intestinal obstruction were reported in one patient each, all in the solifenacin succinate tablets 10 mg group. Angioneurotic edema was reported in one patient taking solifenacin succinate tablets 5 mg. Compared to 12 weeks of treatment with solifenacin succinate tablets, the incidence and severity of adverse reactions were similar in patients who remained on drug for up to 12 months in Study 5 [see Clinical Studies (14)].
The most frequent adverse reaction leading to study discontinuation was dry mouth (1.5%). Table 1 lists the rates of identified adverse reactions, in the four randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with solifenacin succinate tablets 5 or 10 mg once daily for up to 12 weeks.
Table 1: Adverse Reactions Reported by ≥ 1% of Patients and Exceeding Placebo in Studies 1, 2, 3 and 4 Placebo (%) Solifenacin succinate 5 mg (%) Solifenacin succinate 10 mg (%) Number of Patients 1216 578 1233 GASTROINTESTINAL DISORDERS Dry Mouth 4.2 10.9 27.6 Constipation 2.9 5.4 13.4 Nausea 2.0 1.7 3.3 Dyspepsia 1.0 1.4 3.9 Abdominal Pain Upper 1.0 1.9 1.2 Vomiting NOS 0.9 0.2 1.1 INFECTIONS AND INFESTATIONS Urinary Tract Infection NOS 2.8 2.8 4.8 Influenza 1.3 2.2 0.9 Pharyngitis NOS 1.0 0.3 1.1 NERVOUS SYSTEM DISORDERS Dizziness 1.8 1.9 1.8 EYE DISORDERS Vision Blurred 1.8 3.8 4.8 Dry Eyes NOS 0.6 0.3 1.6 RENAL AND URINARY DISORDERS Urinary Retention 0.6 0 1.4 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Edema Lower Limb 0.7 0.3 1.1 Fatigue 1.1 1.0 2.1 PSYCHIATRIC DISORDERS Depression NOS 0.8 1.2 0.8 RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Cough 0.2 0.2 1.1 VASCULAR DISORDERS Hypertension NOS 0.6 1.4 0.5
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of solifenacin succinate in the U.S. and/or outside of the U.S. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General disorders and administration site conditions: peripheral edema, hypersensitivity reactions (including angioedema with airway obstruction, rash, pruritus, urticaria, anaphylactic reaction); Nervous system disorders: dizziness, headache, confusion, hallucinations, delirium, somnolence; Cardiac disorders: QT prolongation, Torsade de Pointes, atrial fibrillation, tachycardia, palpitations; Hepatobiliary disorders: liver disorders mostly characterized by abnormal liver function tests, AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma-glutamyl transferase); Renal and urinary disorders: renal impairment, urinary retention; Metabolism and nutrition disorders: decreased appetite, hyperkalemia; Skin and subcutaneous tissue disorders: exfoliative dermatitis, erythema multiforme, dry skin; Eye disorders: glaucoma; Gastrointestinal disorders: gastroesophageal reflux disease, ileus, vomiting, abdominal pain, dysgeusia, sialadenitis; Respiratory, thoracic and mediastinal disorders: dysphonia, nasal dryness; Musculoskeletal and connective tissue disorders: muscular weakness.
Adverse reaction frequency tables (US label) US FDA label
| Placebo (%) | Solifenacin succinate 5 mg (%) | Solifenacin succinate 10 mg (%) | |
| Number of Patients | 1216 | 578 | 1233 |
| GASTROINTESTINAL DISORDERS | |||
| Dry Mouth | 4.2 | 10.9 | 27.6 |
| Constipation | 2.9 | 5.4 | 13.4 |
| Nausea | 2.0 | 1.7 | 3.3 |
| Dyspepsia | 1.0 | 1.4 | 3.9 |
| Abdominal Pain Upper | 1.0 | 1.9 | 1.2 |
| Vomiting NOS | 0.9 | 0.2 | 1.1 |
| INFECTIONS AND INFESTATIONS | |||
| Urinary Tract Infection NOS | 2.8 | 2.8 | 4.8 |
| Influenza | 1.3 | 2.2 | 0.9 |
| Pharyngitis NOS | 1.0 | 0.3 | 1.1 |
| NERVOUS SYSTEM DISORDERS | |||
| Dizziness | 1.8 | 1.9 | 1.8 |
| EYE DISORDERS | |||
| Vision Blurred | 1.8 | 3.8 | 4.8 |
| Dry Eyes NOS | 0.6 | 0.3 | 1.6 |
| RENAL AND URINARY DISORDERS | |||
| Urinary Retention | 0.6 | 0 | 1.4 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | |||
| Edema Lower Limb | 0.7 | 0.3 | 1.1 |
| Fatigue | 1.1 | 1.0 | 2.1 |
| PSYCHIATRIC DISORDERS | |||
| Depression NOS | 0.8 | 1.2 | 0.8 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | |||
| Cough | 0.2 | 0.2 | 1.1 |
| VASCULAR DISORDERS | |||
| Hypertension NOS | 0.6 | 1.4 | 0.5 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. No adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (MRHD) of 10 mg/day.
However, administration of doses 3.6 times and greater than the MRHD during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see Data]. In the U.S. general population, the estimated background risk of major birth defects or miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data Animal Data Oral administration of 14 C-solifenacin succinate to pregnant mice resulted in the recovery of radiolabel in the fetus indicating that solifenacin-related product can cross the placental barrier. In pregnant mice, administration of solifenacin succinate at a dose of 250 mg/kg/day (7.9 times the systemic exposure at the MRHD of 10 mg), resulted in an increased incidence of cleft palate and increased maternal lethality.
Administration of solifenacin succinate to pregnant mice during organogenesis at greater than or equal to 3.6 times (100 mg/kg/day and greater) the systemic exposure at the MRHD, resulted in reduced fetal body weights and reduced maternal body weight gain. No embryo-fetal toxicity or teratogenicity was observed in fetuses from pregnant mice treated with solifenacin succinate at a dose of 30 mg/kg/day (1.2 times the systemic exposure at the MRHD).
Administration of solifenacin succinate to pregnant rats and rabbits at a dose of 50 mg/kg/day (< 1 times and 1.8 times the systemic exposure at the MRHD, respectively), resulted in no findings of embryo-fetal toxicity. Oral pre- and post-natal administration of solifenacin succinate at 100 mg/kg/day (3.6 times the systemic exposure at the MRHD) during the period of organogenesis through weaning, resulted in reduced peripartum and postnatal survival, reduced body weight gain by the pups, and delayed physical development (eye opening and vaginal patency).
An increase in the percentage of male offspring was also observed in litters from offspring (F2 generation) exposed to maternal doses of 250 mg/kg/day. There were no effects on natural delivery in mice treated with 1.2 times (30 mg/kg/day) the expected systemic exposure at the MRHD.
Mechanism of action
12.1 Mechanism of Action Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Cardiac Electrophysiology The effect of 10 mg and 30 mg solifenacin succinate (three times the maximum recommended dose) on the QT interval was evaluated at the time of peak plasma concentration of solifenacin in a multi-dose, randomized, double-blind, placebo and positive-controlled (moxifloxacin 400 mg) trial [see Warnings and Precautions (5.6)]. After receiving placebo and moxifloxacin sequentially, subjects were randomized to one of two treatment groups.
One group (n=51) completed 3 additional sequential periods of dosing with solifenacin succinate 10, 20, and 30 mg while the second group (n=25) in parallel completed a sequence of placebo and moxifloxacin. Study subjects were female volunteers aged 19 to 79 years. The 30 mg dose of solifenacin succinate (three times the highest recommended dose) was chosen for use in this study because this dose results in a solifenacin exposure that covers those observed upon coadministration of 10 mg solifenacin succinate tablet with strong CYP3A4 inhibitors (e.g. ketoconazole., 400 mg).
Due to the sequential dose escalating nature of the study, baseline ECG measurements were separated from the final QT assessment (of the 30 mg dose level) by 33 days. The median difference from baseline in heart rate associated with the 10 and 30 mg doses of solifenacin succinate compared to placebo was -2 and 0 beats/minute, respectively.
Because a significant period effect on QTc was observed, the QTc effects were analyzed utilizing the parallel placebo control arm rather than the pre-specified intra-patient analysis. Representative results are shown in Table 2. Table 2: QTc changes in msec (90% CI) from baseline at T max (relative to placebo) 1 Drug/Dose Fridericia method (using mean difference) Solifenacin succinate 10 mg 2 (-3,6) Solifenacin succinate 30 mg 8 (4, 13) 1 Results displayed are those derived from the parallel design portion of the study and represent the comparison of Group 1 to time-matched placebo effects in Group 2 2 Moxifloxacin was included as a positive control in this study and, given the length of the study, its effect on the QT interval was evaluated in 3 different sessions.
The placebo subtracted mean changes (90% CI) in QTcF for moxifloxacin in the three sessions were 11 (7, 14), 12 (8, 17), and 16 (12, 21), respectively. The QT interval prolonging effect of the highest solifenacin succinate dose (three times the maximum therapeutic dose) studied was not as large as that of the positive control moxifloxacin at its recommended dose.
However, the confidence intervals overlapped, and this study was not designed to draw direct statistical conclusions between the drugs or the dose levels.
Pharmacokinetics
Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45-68 hours.
Excretion Following the administration of 10 mg of 14 C-solifenacin succinate to healthy volunteers, 69% of the radioactivity was recovered in the urine and 23% in the feces over 26 days.
Specific Populations Geriatric Patients Multiple dose studies of solifenacin succinate tablet in geriatric volunteers (65 to 80 years) showed that Cmax, AUC and t1/2 values of solifenacin were 20-25% higher compared to the younger adult volunteers (18 to 55 years).
Patients with Renal Impairment In studies with solifenacin succinate 10 mg, there was a 2.1-fold increase in AUC and a 1.6-fold increase in t1/2 of solifenacin in patients with severe renal impairment compared to subjects with normal renal function [see Use in Specific Populations ( 8.6 )].
Patients with Hepatic Impairment In studies with solifenacin succinate 10 mg, there was a 2-fold increase in the t1/2 and a 35% increase in AUC of solifenacin in patients with moderate hepatic impairment compared to subjects with normal hepatic function [see Use in Specific Populations ( 8.7 )].
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption After oral administration of solifenacin succinate tablet in healthy volunteers, peak plasma concentrations (Cmax) of solifenacin were reached within 3 to 8 hours after administration and, at steady-state, ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg solifenacin succinate tablet tablets, respectively. The absolute bioavailability of solifenacin is approximately 90%, with plasma concentrations of solifenacin proportional to the dose administered.
Effect of Food Solifenacin succinate tablet may be administered without regard to meals. A single 10 mg dose administration of solifenacin succinate tablets with food increased C max and AUC of solifenacin by 4% and 3%, respectively. Distribution Solifenacin is approximately 98% (in vivo) bound to human plasma proteins, principally to ∝1-acid glycoprotein.
Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L. Elimination The elimination half-life (t1/2) of solifenacin following chronic dosing is approximately 45-68 hours. Metabolism Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist.
The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of the tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing.
Excretion Following the administration of 10 mg of 14 C-solifenacin succinate to healthy volunteers, 69% of the radioactivity was recovered in the urine and 23% in the feces over 26 days. Less than 15% (as mean value) of the dose was recovered in the urine as intact solifenacin. The major metabolites identified in urine were N-oxide of solifenacin, 4R-hydroxy solifenacin, and 4R-hydroxy-N-oxide of solifenacin and, in feces, 4R-hydroxy solifenacin.
Specific Populations Geriatric Patients Multiple dose studies of solifenacin succinate tablet in geriatric volunteers (65 to 80 years) showed that Cmax, AUC and t1/2 values of solifenacin were 20-25% higher compared to the younger adult volunteers (18 to 55 years). [See Use in Specific Populations (8.5)]. Patients with Renal Impairment In studies with solifenacin succinate 10 mg, there was a 2.1-fold increase in AUC and a 1.6-fold increase in t1/2 of solifenacin in patients with severe renal impairment compared to subjects with normal renal function [see Use in Specific Populations (8.6)].
Patients with Hepatic Impairment In studies with solifenacin succinate 10 mg, there was a 2-fold increase in the t1/2 and a 35% increase in AUC of solifenacin in patients with moderate hepatic impairment compared to subjects with normal hepatic function [see Use in Specific Populations (8.7)]. Solifenacin succinate has not been studied in patients with severe hepatic impairment.
Drug Interaction Studies Strong CYP3A4 Inhibitors In a crossover study, following blockade of CYP3A4 by coadministration of the strong CYP3A4 inhibitor, ketoconazole 400 mg once daily for 21 days, the mean C max and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively [see Dosage and Administration (2.4) and Drug Interactions (7.1)]. CYP3A4 Inducers Because solifenacin is a substrate of CYP3A4, inducers of CYP3A4 may decrease the concentration of solifenacin.
Warfarin In a crossover study, subjects received a single oral dose of warfarin 25 mg on the 10th day of dosing with either solifenacin succinate10 mg or matching placebo once daily for 16 days. For R-warfarin, when it was coadministered with solifenacin succinate, the mean C max increased by 3% and AUC decreased by 2%.
For S-warfarin, when it was coadministered with solifenacin succinate, the mean C max and AUC increased by 5% and 1%, respectively. Oral Contraceptives In a crossover study, subjects received 2 cycles of 21 days of oral contraceptives containing 30 ug ethinyl estradiol and 150 ug levonorgestrel. During the second cycle, subjects received additional solifenacin succinate 10 mg or matching placebo once daily for 10 days starting from the 12th day of receipt of oral contraceptives.
For ethinyl estradiol, when it was administered with solifenacin succinate, the mean C max and AUC increased by 2% and 3%, respectively. For levonorgestrel, when it was administered with solifenacin succinate, the mean C max and AUC decreased by 1%. Digoxin In a crossover study, subjects received digoxin (loading dose of 0.25 mg on day 1, followed by 0.125 mg from days 2 to 8) for 8 days.
Consecutively, they received solifenacin succinate 10 mg or matching placebo with digoxin 0.125 mg for an additional 10 days. When digoxin was coadministered with solifenacin succinate, the mean C max and AUC increased by 13% and 4%, respectively. Drugs Metabolized by Cytochrome P450 Enzymes In vitro studies demonstrated that, at therapeutic concentrations, solifenacin does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver microsomes.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. solifenacin succinate · Macleods Pharmaceuticals Limited [US FDA-approved label, version 2, September 22, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbd6e753-1ed2-418a-8667-c674b215eabb
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .